Cargando…
The prospect of orally administered monoclonal secretory IgA (SIgA) antibodies to prevent enteric bacterial infections
Eliminating diarrheal diseases as a leading cause of childhood morbidity and mortality in low- and middle-income countries (LMICs) will require multiple intervention strategies. In this review, we spotlight a series of preclinical studies investigating the potential of orally administered monoclonal...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9103515/ https://www.ncbi.nlm.nih.gov/pubmed/34491878 http://dx.doi.org/10.1080/21645515.2021.1964317 |
_version_ | 1784707574330818560 |
---|---|
author | Richards, Angelene Baranova, Danielle Mantis, Nicholas J. |
author_facet | Richards, Angelene Baranova, Danielle Mantis, Nicholas J. |
author_sort | Richards, Angelene |
collection | PubMed |
description | Eliminating diarrheal diseases as a leading cause of childhood morbidity and mortality in low- and middle-income countries (LMICs) will require multiple intervention strategies. In this review, we spotlight a series of preclinical studies investigating the potential of orally administered monoclonal secretory IgA (SIgA) antibodies (MAbs) to reduce disease associated with three enteric bacterial pathogens: Campylobacter jejuni, enterotoxigenic Escherichia coli (ETEC), and invasive Salmonella enterica serovar Typhimurium. IgA MAbs targeting bacterial surface antigens (flagella, adhesins, and lipopolysaccharide) were generated from mice, humanized mice, and human tonsillar B cells. Recombinant SIgA1 and/or SIgA2 derivates of those MAbs were purified from supernatants following transient transfection of 293 cells with plasmids encoding antibody heavy and light chains, J-chain, and secretory component (SC). When administered to mice by gavage immediately prior to (or admixed with) the bacterial challenge, SIgA MAbs reduced infection C. jejuni, ETEC, and S. Typhimurium infections. Fv-matched IgG1 MAbs by comparison were largely ineffective against C. jejuni and S. Typhimurium under the same conditions, although they were partially effective against ETEC. While these findings highlight future applications of orally administered SIgA, the studies also underscored the fundamental challenges associated with using MAbs as prophylactic tools against enteric bacterial diseases. |
format | Online Article Text |
id | pubmed-9103515 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-91035152022-05-14 The prospect of orally administered monoclonal secretory IgA (SIgA) antibodies to prevent enteric bacterial infections Richards, Angelene Baranova, Danielle Mantis, Nicholas J. Hum Vaccin Immunother Passive SF – Reviews Eliminating diarrheal diseases as a leading cause of childhood morbidity and mortality in low- and middle-income countries (LMICs) will require multiple intervention strategies. In this review, we spotlight a series of preclinical studies investigating the potential of orally administered monoclonal secretory IgA (SIgA) antibodies (MAbs) to reduce disease associated with three enteric bacterial pathogens: Campylobacter jejuni, enterotoxigenic Escherichia coli (ETEC), and invasive Salmonella enterica serovar Typhimurium. IgA MAbs targeting bacterial surface antigens (flagella, adhesins, and lipopolysaccharide) were generated from mice, humanized mice, and human tonsillar B cells. Recombinant SIgA1 and/or SIgA2 derivates of those MAbs were purified from supernatants following transient transfection of 293 cells with plasmids encoding antibody heavy and light chains, J-chain, and secretory component (SC). When administered to mice by gavage immediately prior to (or admixed with) the bacterial challenge, SIgA MAbs reduced infection C. jejuni, ETEC, and S. Typhimurium infections. Fv-matched IgG1 MAbs by comparison were largely ineffective against C. jejuni and S. Typhimurium under the same conditions, although they were partially effective against ETEC. While these findings highlight future applications of orally administered SIgA, the studies also underscored the fundamental challenges associated with using MAbs as prophylactic tools against enteric bacterial diseases. Taylor & Francis 2021-09-07 /pmc/articles/PMC9103515/ /pubmed/34491878 http://dx.doi.org/10.1080/21645515.2021.1964317 Text en © 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. |
spellingShingle | Passive SF – Reviews Richards, Angelene Baranova, Danielle Mantis, Nicholas J. The prospect of orally administered monoclonal secretory IgA (SIgA) antibodies to prevent enteric bacterial infections |
title | The prospect of orally administered monoclonal secretory IgA (SIgA) antibodies to prevent enteric bacterial infections |
title_full | The prospect of orally administered monoclonal secretory IgA (SIgA) antibodies to prevent enteric bacterial infections |
title_fullStr | The prospect of orally administered monoclonal secretory IgA (SIgA) antibodies to prevent enteric bacterial infections |
title_full_unstemmed | The prospect of orally administered monoclonal secretory IgA (SIgA) antibodies to prevent enteric bacterial infections |
title_short | The prospect of orally administered monoclonal secretory IgA (SIgA) antibodies to prevent enteric bacterial infections |
title_sort | prospect of orally administered monoclonal secretory iga (siga) antibodies to prevent enteric bacterial infections |
topic | Passive SF – Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9103515/ https://www.ncbi.nlm.nih.gov/pubmed/34491878 http://dx.doi.org/10.1080/21645515.2021.1964317 |
work_keys_str_mv | AT richardsangelene theprospectoforallyadministeredmonoclonalsecretoryigasigaantibodiestoprevententericbacterialinfections AT baranovadanielle theprospectoforallyadministeredmonoclonalsecretoryigasigaantibodiestoprevententericbacterialinfections AT mantisnicholasj theprospectoforallyadministeredmonoclonalsecretoryigasigaantibodiestoprevententericbacterialinfections AT richardsangelene prospectoforallyadministeredmonoclonalsecretoryigasigaantibodiestoprevententericbacterialinfections AT baranovadanielle prospectoforallyadministeredmonoclonalsecretoryigasigaantibodiestoprevententericbacterialinfections AT mantisnicholasj prospectoforallyadministeredmonoclonalsecretoryigasigaantibodiestoprevententericbacterialinfections |